Open – We are accepting applications for new and renewal patients. If your application for assistance is approved you can begin receiving funding immediately.
$8,500 per year. Patients may apply for a second grant during their eligibility period subject to availability of funding.
- The patient must be getting treatment for Philadelphia chromosome negative myeloproliferative neoplasms.
- The patient must have health insurance that covers his or her qualifying medication or product.
- The patient’s medication or product must be listed on PAN’s list of covered medications.
- The patient’s income must fall at or below 500% of the Federal Poverty Level.
- The patient must reside and receive treatment in the United States or U.S. territories. (U.S. citizenship is not a requirement.)
See the list of medications covered in this program
- Agrylin (anagrelide hcl)
- Alkeran (melphalan hcl)
- Anagrelide Hcl (anagrelide hcl)
- Busulfex (busulfan)
- Cladribine (cladribine)
- Danazol (danazol)
- Deferasirox (deferasirox)
- Deltasone (prednisone)
- Droxia (hydroxyurea)
- Exjade (deferasirox)
- Gleevec (imatinib mesylate)
- Hydrea (hydroxyurea)
- Hydroxyurea (hydroxyurea)
- Imatinib Mesylate (imatinib mesylate)
- Intron A (interferon alfa-2b,recomb.)
- Jakafi (ruxolitinib phosphate)
- Medrol (methylprednisolone)
- Melphalan Hcl (melphalan hcl)
- Myleran (busulfan)
- Pegasys (peginterferon alfa-2a)
- Pegasys Proclick (peginterferon alfa-2a)
- Pegintron Redipen (peginterferon alfa-2b)
- Pomalyst (pomalidomide)
- Prednisone (prednisone)
- Revlimid (lenalidomide)
- Sylatron (peginterferon alfa-2b)
- Thalomid (thalidomide)
ICD-10: C92.20, C92.21, C92.22, C94.40, C94.41, C94.42, D45, D47.1, D47.3, D47.4
About the Disease:
Philadelphia chromosome negative myeloproliferative neoplasms (MPN) is a cancer associated with increased production of blood cells. MPN affects the circulatory system. Subtypes include essential thrombocythemia, myelofibrosis and polycythemia vera.
Source: National Institutes of Health